Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Oncogenic mutations regulate tumor microenvironment through induction of growth factors and angiogenic mediators.

Oncogene - 10 Jun 2010

Wang S E, Yu Y, Criswell T L, Debusk L M, Lin P C, Zent R, Johnson D H, Ren X, Arteaga C L

Abstract excerpt

Activating mutations in the tyrosine kinase domain of HER2 (ErbB2) have been identified in human cancers. Compared with wild-type HER2, mutant HER2 shows constitutively activate kinase activity and increased oncogenicity. Cells transformed by mutant HER2 are resistant to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors and exhibit an attenuated response to the HER2 antibody trastuzumab. We...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to ErbB Receptors
Share to JNK Mitogen-Activated Protein Kinases

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Proto-Oncogene Proteins p21(ras)

Share to rac1 GTP-Binding Protein

Share to Receptor, ErbB-2

Share to Transcription Factor AP-1

Share to Transforming Growth Factor beta1

Share to Vascular Endothelial Growth Factor A

Source

Open in PubMed Open full text

Identifiers

PMID: 20383197
DOI: 10.1038/onc.2010.112
PMCID: PMC2883631

Genes

EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Oncogenic mutations regulate tumor microenvironment through induction of growth factors and angiogenic mediators.PMID 20383197Read ↗

The Functional Crosstalk between HER2 Tyrosine Kinase and TGF-<i>β</i>Signaling in Breast Cancer MalignancySemantic proximity Read ↗

The oncogene HER2: its signaling and transforming functions and its role in human cancer pathogenesis.Semantic proximity Read ↗

ERBB2-Mediated Transcriptional Up-regulation of the α5β1 Integrin Fibronectin Receptor Promotes Tumor Cell Survival Under Adverse ConditionsSemantic proximity Read ↗

Mechanisms for oncogenic activation of the epidermal growth factor receptor.Semantic proximity Read ↗

Signal integration: a framework for understanding the efficacy of therapeutics targeting the human EGFR familySemantic proximity Read ↗

Mammary Tumor Formation and Metastasis Evoked by a HER2 Splice VariantSemantic proximity Read ↗

Role of HER2/neu in tumor progression and therapy.Semantic proximity Read ↗

Differential gene expression analysis reveals generation of an autocrine loop by a mutant epidermal growth factor receptor in glioma cells.Semantic proximity Read ↗

Ligand-independent oncogenic signaling by the epidermal growth factor receptor: v-ErbB as a paradigm.Semantic proximity Read ↗

Transforming Growth Factor-beta Regulation of Ephrin Type-A Receptor 4 Signaling in Breast Cancer Cellular Migration.Semantic proximity Read ↗

Therapeutic IMC-C225 antibody inhibits breast cancer cell invasiveness via Vav2-dependent activation of RhoA GTPase.Semantic proximity Read ↗

HER2 induced EMT and tumorigenicity in breast epithelial progenitor cells is inhibited by coexpression of EGFR.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.